Eli Lilly and Company and Evonik Industries have renewed a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly’s human and veterinary drug products.

Evonik acquired Lilly’s Tippecanoe site in Lafayette, Indiana in 2010. The facility has been operating as a contract development and manufacturing organization since then. The facility has 170 cubic meters of high-potency APIs capacity and a total of 860 cubic meters of cGMP manufacturing capacity.

The Lafayette site employs approximately 600 people. Evonik’s product and service portfolio includes API contract manufacturing, pharmaceutical excipients, advanced food ingredients, amino acids, cell-culture ingredients as well as oral and parenteral drug-delivery technologies.

Source: Evonik Industries